ResMed Inc Stock News

ResMed's (RMD) Q2 results reflect cost discipline to support an acceleration in profitability.

ResMed topped consensus Wall Street revenue and earnings estimates with its fiscal Q2 results. The company delivered double-digit-percentage growth across all of its products and services.

ResMed Inc. (RMD) Q2 2024 Earnings Call Transcript

While the top- and bottom-line numbers for ResMed (RMD) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare

ResMed (RMD) came out with quarterly earnings of $1.88 per share, beating the Zacks Consensus Estimate of $1.81 per share. This compares to earnings of $1.66 per share a year ago.

ResMed beat Wall Street estimates for second-quarter revenue and profit on Wednesday, powered by strong demand for its respiratory devices used to treat sleep apnea.

Google “How important is sleep?” and you get three billion results.

I opine RMD is now attractively valued given its long-term stability and its product is highly demanded. ResMed's product is in high demand in the modern obesity epidemic. A new weight loss drug will

Evaluate the expected performance of ResMed (RMD) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics f

Investors are optimistic about ResMed (RMD) on strong uptake of the myAir app with AirSense11.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

The U.S. Food and Drug Administration (FDA) on Thursday classified the recall of certain respiratory masks made by ResMed as most serious as their use could cause major injuries or death.

ResMed is a profitable company with steady growth and attractive margins, making it a solid investment opportunity. The company operates mainly in the sleep apnea market, which is expected to grow sig

SAN DIEGO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2024 on Wednesday,

ResMed's shares have fallen 37% due to struggles with profitability and investor fears of weight loss drugs, but I believe in its long-term potential. The company reported a 16% increase in revenue an